Mitapivat Sulfate Patent Expiration

Mitapivat Sulfate is used for treating hemolytic anemia in adults with pyruvate kinase (PK) deficiency. It was first introduced by Agios Pharmaceuticals Inc in its drug Pyrukynd on Feb 17, 2022.


Mitapivat Sulfate Patents

Given below is the list of patents protecting Mitapivat Sulfate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Pyrukynd US10632114 Pyruvate kinase activators for use in therapy May 03, 2032 Agios Pharms Inc
Pyrukynd US11234976 Methods of using pyruvate kinase activators Oct 11, 2038 Agios Pharms Inc
Pyrukynd US11254652 Crystalline forms of N-(4-(4-(cyclopropymethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide Nov 21, 2038 Agios Pharms Inc
Pyrukynd US11793806 Pyruvate kinase activators for use in therapy Apr 12, 2033 Agios Pharms Inc
Pyrukynd US11878049 Mitapivat therapy and modulators of cytochrome P450 Jul 31, 2041 Agios Pharms Inc
Pyrukynd US8785450 Therapeutic compounds and compositions Feb 24, 2031 Agios Pharms Inc
Pyrukynd US9193701 Pyruvate kinase activators for use in therapy Oct 26, 2032 Agios Pharms Inc
Pyrukynd US9682080 Pyruvate kinase activators for use in therapy May 03, 2032 Agios Pharms Inc
Pyrukynd US9980961 Pyruvate kinase activators for use in therapy May 03, 2032 Agios Pharms Inc
Pyrukynd USRE49582 Therapeutic compounds and compositions Feb 24, 2031 Agios Pharms Inc


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Mitapivat Sulfate's patents.

Given below is the list recent legal activities going on the following patents of Mitapivat Sulfate.

Event Date Patent/Publication
Patent litigations
transaction for FDA Determination of Regulatory Review Period 14 Mar, 2024 US9193701
transaction for FDA Determination of Regulatory Review Period 28 Feb, 2024 US9193701
Mail Patent eCofC Notification 27 Feb, 2024 US11878049
Recordation of Patent eCertificate of Correction 27 Feb, 2024 US11878049
Patent eCofC Notification 27 Feb, 2024 US11878049
Email Notification 27 Feb, 2024 US11878049
Post Issue Communication - Certificate of Correction 05 Feb, 2024 US11878049
Mail Patent eGrant Notification 23 Jan, 2024 US11878049
Email Notification 23 Jan, 2024 US11878049
Patent eGrant Notification 23 Jan, 2024 US11878049



Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳